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Abstract
Purpose Nerve growth factor (NGF) expression and
activity is important in chronic lower back pain but may
also act as a pro-catabolic factor in the pathogenesis of
intervertebral disc (IVD) degeneration. Lipocalin 2 (Lcn2)
expression in IVD was upregulated by NGF stimulation in
our previous study. The current study was undertaken to
identify potential mechanisms of the latter effect including
potential interactions between Lcn2 and matrix metallo-
proteinase 9 (MMP9).
Methods Rat annulus fibrosus (AF) cells were stimulated
by NGF and subjected to microarray analysis, subsequent
real-time PCR, western immunoblotting, and immunoflu-
orescence. Cells were treated with NGF in the absence or
presence of the NGF inhibitor Ro 08-2750. Zymography
and functional MMP9 assays were used to determine
MMP9 activity, whilst the dimethyl-methylene blue assay
was used to quantify the release of glycosaminoglycans
(GAGs) reflecting catabolic effects following NGF treat-
ment. Immunoprecipitation with immunoblotting was used
to identify interactions between MMP9 and Lcn2.
Results Increased expression of Lcn2 gene and protein
following NGF stimulation was confirmed by microarray
analysis, real-time PCR, western blot and immunofluores-
cence. Zymography showed that NGF enhanced 125-kDa
gelatinase activity, identified as a Lcn2/MMP9 complex by
immunoprecipitation and immunoblotting. Functional
assays showed increased MMP9 activity and GAG release
in the presence of NGF. The effects of NGF were neu-
tralized by the presence of Ro 08-2750.
Conclusions NGF upregulates Lcn2 expression and
increases MMP9 activity in AF cells; processes which are
likely to potentiate degeneration of AF tissue in vivo. Anti-
NGF treatment may have benefit for management of painElectronic supplementary material The online version of this
article (doi:10.1007/s00586-014-3675-2) contains supplementary
material, which is available to authorized users.
T.-H. Kao  H.-S. Lee
Graduate Institute of Medical Science, National Defense
Medical Center, Taipei, Taiwan, Republic of China
T.-H. Kao
Functional Neurosurgery Division, Neurological Institute,
Taichung Veterans General Hospital, Taichung, Taiwan,
Republic of China
T.-H. Kao
Department of Acupressure Technology, Jen-Teh Junior College
of Medicine, Nursing and Management, Miaoli County, Taiwan,
Republic of China
Y.-J. Peng  H.-S. Lee
Department of Pathology, Tri-Service General Hospital and
National Defense Medical Center, Taipei, Taiwan,
Republic of China
D. M. Salter
Osteoarticular Research Group, Centre for Genomics and
Experimental Medicine, Institute of Genetics and Molecular
Medicine, University of Edinburgh, Edinburgh, UK
H.-S. Lee (&)
Department of Pathology and Laboratory Medicine, Kaohsiung
Veterans General Hospital, No. 386, Dazhong 1st Rd., Zuoying




Eur Spine J (2015) 24:1959–1968
DOI 10.1007/s00586-014-3675-2
relief and slowing down progression of AF tissue
degeneration.
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Introduction
Chronic low back pain (LBP) is a relatively common
condition with a number of possible etiologies including
intervertebral disc (IVD) degeneration, spondylolisthesis,
diskitis or spondylitis [1, 2]. The pathogenesis of the
chronic LBP associated with IVD degeneration is complex
but changes in IVD innervation appear to be important [3].
In the normal IVD, nerve fibers, derived from branches of
sympathetic trunk and sinuvertebral nerves, are present
only in the outer annulus fibrosus (AF) and vertebral
endplate [4]. During IVD degeneration, however, nerve
fiber ingrowth into the nucleus pulposus (NP) is seen and is
believed to possibly contribute to chronic LBP [5]. Con-
sequent therapies targeting neuronal transmission pathways
are increasingly being thought to be useful for alleviating
pain [6, 7]. It is becoming clear, however, that neurotro-
phins such as NGF and brain-derived neurotrophic factor
(BDNF) have a wide range of activities other than neuro-
transmission that include roles in tissue development,
repair, modulation of inflammatory responses and bone and
cartilage metabolism [8–11].
In addition to inducing nerve ingrowth, NGF appears
to have other effects that are likely to contribute IVD
degeneration. Matrix degradation as a result of over
production of matrix metalloproteinases (MMPs) is a
major component of the pathological processes that lead
to IVD degeneration [12] and NGF has been shown to
increase MMP expression in a number of tissues and cell
systems [13]. Furthermore, NGF has been shown to
induce neoangiogenesis in a range of normal and patho-
logical conditions [14]. As such NGF appears to be a
prime target for intervention in the course of IVD
degeneration with the potential to both ameliorate pain
and decrease or reverse the rate of disease progression.
NGF influences expression of several catabolic genes in
animal and human IVD cells including ch3l1, lipocalin 2
(lcn2), mmp3 and mmp13 according to our previous
microarray-based study [15]. Since Lcn2 protein has been
reported as forming a complex with MMP9 to protect it
from degradation and thereby enhancing its catabolic
function in osteoarthritic cartilage [16], the current study
was undertaken to test the hypothesis that NGF regulates
expression of lipocalin 2 in AF cells resulting in an
increase in MMP9 activity which would potentially
contribute to IVD degeneration.
Materials and methods
Experimental animals and ethics statement
Two-month-old skeletally mature male Sprague–Dawley
rats (weight 380–420 g) were obtained from the National
Applied Research Laboratories and National Laboratory
Animal Center (Taiwan). All experimental procedures were
approved by the Institutional Animal Care and Use Com-
mittee of Taichung Veterans General Hospital (La-101983).
Reagents
Rat beta-nerve growth factor (NGF) was purchased from
R&D System Inc. (Minneapolis, MN, USA). NGF stock
solution at a concentration of 100 lg/mL was prepared in
sterile phosphate-buffered saline (PBS) containing 0.1 %
bovine serum albumin (BSA). Ro 08-2750 was purchased
from TOCRIS bioscience (Bristol, UK). A stock solution at
a concentration of 10 lM was prepared in dimethyl sulf-
oxide (DMSO). Rat IL-1b was purchased from R&D
Systems Inc. IL-1b stock solution at a concentration of
100 lg/mL was prepared in PBS containing 0.1 % BSA.
Isolation and expansion of rat disc cells
AF tissue of rat-tail intervertebral discs (Coccygeal Co4th–
Co6th level) was dissected carefully with minimal NP or
other tissue contamination by an experienced spinal surgeon.
The dissected tissue was then cut into small pieces, incu-
bated with antimicrobial solution for 4 h and then washed
with sterile PBS before digestion with 3 mg/mL collagenase
type H (Sigma-Aldrich Inc., St. Louis, MO, USA) at 37 C
for 6 h. The resultant cell suspension was centrifuged at
1,000 rpm for 10 min following which the supernatant was
discarded and the pellet re-suspended in PBS. After a further
wash, cells were re-suspended and seeded in 10 mL of
Dulbecco’s modified Eagle’s medium/Nutrient Mixture
F-12 HAMmedium (Gibco, Carlsbad, CA, USA) containing
10 % FBS (Gibco), 100 IU/mL penicillin (Gibco) and
100 mg/mL streptomycin (Gibco). The cells were then cul-
tured in a humidified 5 % CO2 incubator at 37 C until
confluent. Cells between passages 3 and 5 were used.
Experimental protocol
Cells were seeded at a density of 1 9 106 cells/dish in
60-mm Petri dishes. Dishes of rat disc cells were placed in
3 % FBS media, then incubated with either 100 ng/mL/day
of NGF and/or 10 nM/day of Ro 08-2750 at 37 C for
5 days. Media were collected for immunoprecipitation and
Fluorescence Resonance Energy Transfer (FRET)-based
assay.
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Microarray assay
The detailed microarray methods and results were provided
in our previous study [15]. Briefly, gene expression ana-
lysis of rat-tail disc cells with or without NGF stimulation
for 5 days was undertaken using the Rat Whole Genome
OneArrayTM (Phalanx Biotech Group, Hsinchu, Taiwan),
signals being scanned by an Axon 4000 scanner (Molecular
Devices, Sunnyvale, CA, USA). The fluorescent intensity
of each spot was analyzed by genepix 4.1 software
(Molecular Devices) with the signal intensity of each spot
being corrected by subtracting the background signal. The
fold change of gene expression was calculated by dividing
the normalized signal intensities of genes in NGF treated
cells by those of untreated cells. Genes with fold changes
[2 or\-2 were analyzed by Kyoto Encyclopedia of Gene
and Genomes (KEGG) pathways on the Gene Ontology
Tree Machine web site, a respected web-based and tree-
based data mining environment for gene sets. We used the
gene Set Test function implemented in the limma R
package (Gordon Smyth) to test significant KEGG path-
ways. The Web Gestalt tool was used to test significant GO
terms. The microarray data comply with MIAME guide-
lines, and the raw data have been deposited in a MIAME-
compliant database. The GEO microarray data number is
GSE49560.
RNA extraction and real-time polymerase chain
reaction
Total RNA from cell cultures was extracted using TRIzol
RNA Isolation Reagents (Invitrogen, NY, USA). For first-
strand complementary DNA synthesis, 2 lg of total RNA
was used in a single-round reverse transcription reaction by
High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA, USA). Complement DNAs
were amplified under the following condition: 95 C for
10 min, 40 cycles of 95 C for 15 s and 60 C for 60 s,
using the Power SYBR green PCR master mix (Applied
Biosystems) and a StepOneTM Real-Time PCR System
(Applied Biosystems). Amplification of glyceraldehyde-3-
phosphate dehydrogenase (Gapdh) simultaneously served
as an internal control and allowed normalization of the
various mRNA levels against the total mRNA content in
the samples which was used to calculate changes in gene
expression by 2-DDCt formula. The specific primers used in
this study are shown in Table 1.
Protein extraction and western blotting
Following stimulation, cells were immediately washed
with ice-cold PBS containing 100 lM Na3VO4 (Sigma)
and lysed in situ with ice-cold lysis buffer at 4 C for
15 min. Lysis buffer contained 1 % Igepal (Sigma),
100 lM Na3VO4, and protease inhibitor cocktail tablet
(Roche Diagnostics, Mannheim, Germany). Whole cell
lysates were collected after centrifugation at 13,000 rpm
for 15 min. Protein concentrations were determined by the
Lowry method. Equal amounts of protein were loaded onto
10 % SDS-polyacrylamide gel and subsequently trans-
ferred to polyvinylidene fluoride (PVDF) membranes
(Millipore). Membranes were blocked overnight at 4 C
with 2 % BSA in TBST. After washing three times with
TBST, blots were incubated overnight with primary anti-
Lcn2 antibody (1:1,000) (Abcam Ltd., Cambridge, UK)
diluted in 2 % BSA. After washing six times with TBST,
blots were then incubated with the HRP-labeled secondary
antibody for 1 h at room temperature. Membranes were
rewashed extensively and antibody binding was detected
using an enhanced chemiluminescence (ECL) plus Western
blotting detection system (Amersham Biosciences, Buck-
inghamshire, UK) according to the manufacturer’s
instructions. The membranes were scanned and analyzed
by densitometry (Fujifilm, LAS 300, Tokyo, Japan).
Immunofluorescence
After incubation with NGF for 5 days, cells were washed
twice with ice-cold PBS and then fixed using 2 mL of a 1:1
methanol/acetone mixture for 5 min at -20 C. For
immunofluorescence, cells were washed twice with PBS
before incubation with 1 % BSA for 30 min at room
temperature. The solution was removed and cells were
incubated sequentially with primary antibody [either anti-
Lcn2 (1:100) or anti-MMP9 (1:100) (Abcam Ltd., Cam-
bridge, UK)] for 60 min, Alexa fluoro dye-conjugated
secondary antibody (1:200) (Invitrogen, USA) for 45 min.
Following each incubation, cells were washed three times
with Tris-buffered saline/Tween (TBST) (2.5 mM Tris/
HCl, pH 7.6, 137 mM NaCl, 0.1 % Tween 20), counter-
stained with DAPI (1:10,000) (Invitrogen) and visualized
under fluorescence microscopy.
Table 1 Oligonucleotides primers for rat real-time PCR analysis
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Zymography
The culture medium was collected and mixed with sample
buffer containing sodium dodecyl sulfate (SDS), glycerol
and bromophenol blue. Equal amounts of each sample were
separated on an SDS-polyacrylamide gel (8 %) containing
1 mg/mL gelatin. After SDS-polyacrylamide gel electro-
phoresis, the gels were washed twice with 2.5 % Triton
X-100 for 30 min to remove SDS, then twice with distilled
water and were finally equilibrated with incubation buffer
(100 mM Tris/HCl, 30 mM CaCl2, 0.01 % NaN3). The gel
was then incubated in incubation buffer for 20 h at 37 C
before staining with Coomassie Blue solution (10 mL of
acetic acid, 40 mL of distilled water, 50 mL of methanol,
0.25 % Coomassie Blue G250) for 40 min. Destaining was
performed in methanol/acetic acid/distilled water.
Quantitation of glycosaminoglycans
Total glycosaminoglycan (GAG) release was measured in
media collected at day 5 using 1,9-dimethylmethylene blue
(DMMB) assay. DMMB solution was prepared by dis-
solving 16 mg DMMB (Sigma-Aldrich), 3.04 g glycine
and 2.37 g NaCl in deionized water (final volume 1 L, pH
3.0). Standards were chondroitin sulfate sodium salt from
shark cartilage (Sigma-Aldrich) soluble in PBS buffer,
prepared ranging from 0 to 150 lg/mL. 25 lL of sample
was added to a well of a 96-well plate followed immedi-
ately by addition of 125 lL DMMB solution. Absorbance
was measured at 525 nm by use of EnSpire multimode
plate reader (PerkinElmer Inc., MA, USA).
Immunoprecipitation and FRET assay
Cultured media in the conditions of control, NGF, Ro
08-2750 and NGF ? Ro 08-2750 were collected. For each
condition, 3 mL of medium was concentrated to 0.5 mL
with Spin-X UF centrifugal concentrators at 1,500 rpm for
1 h at 4 C (Corning, MA, USA). Protein concentrations
were determined by the Lowry method. Equal amounts of
500 lg protein were incubated with anti-MMP9 antibody
(1 mg/mL, 1 lL) overnight and immunoprecipitated with a
Protein G Immunoprecipitation Kit (Sigma). Pull-down
products were loaded onto 10 % SDS-polyacrylamide gel
and subsequently transferred to PVDF membranes (Milli-
pore). Membranes were blocked overnight at 4 C with
2 % BSA in TBST. After washing three times with TBST,
blots were incubated overnight with primary anti-Lcn2 or
anti-MMP9 antibody (1:1,000) (Abcam) diluted in 2 %
BSA. After washing six times with TBST, blots were then
incubated with the HRP-labeled secondary antibody for 1 h
at room temperature. Membranes were rewashed
extensively and antibody binding was detected using an
ECL plus Western blotting detection system (Amersham
Biosciences) according to the manufacturer’s instructions.
The membranes were scanned and analyzed by densitom-
etry (Fujifilm, LAS 300).
FRET assays were carried out according to the man-
ufacturer’s instructions. Briefly, MMP9 antibody (Ab-
cam, Bristol, UK) was coupled to the resin. Cultured
media were incubated with MMP9 antibody-coupled
resin. Non-bound proteins were removed by washing and
bound proteins were eluted with a low pH buffer. The
eluted supernatant was incubated with AMPA (4-amin-
ophenylmercuric acetate) for 2 h at 37 C and then added
to a MMP9 substrate solution using MMP9 assay kit
(AnaSpec Inc., CA, USA). The fluorescence intensity was
measured immediately using Synergy H4 (BioTek, VT,
USA) with a filter set of excitation/emission = 485 ±
20 nm/528 ± 20 nm.
Statistical analysis
All values were expressed as mean ± standard deviation
(SD). Statistical evaluation of the quantification data of
mRNA and protein expression levels was performed by
Student’s t tests. The results were considered significant at
a P value\0.05.
Results
Effect of NGF on annulus fibrosus cell gene expression
Using purified RNA samples from the AF cells, we found
that 97 of the 24,358 transcripts (\0.4 %) covered by Rat
OneArray showed[twofold change after NGF stimulation
[15]. The top 30 upregulated genes by a log2 ratio of more
than 1.5 are shown as supplementary data. NGF had no
effect on cell viability over the time course of the experi-
ment as assessed by an MTT assay (data not shown).
NGF increases Lcn2 gene and protein expression in rat
AF cells
Among the genes identified as being upregulated in the
microarray study, Lcn2 was selected for further investiga-
tion in view of previous published work that indicates
potential roles for this molecule in protecting MMP9
activity on cartilage matrix breakdown [16]. Real-time
PCR confirmed increased expression of Lcn2 following
NGF stimulation (Fig. 1a). Western blotting demonstrated
increased expression of Lcn2 protein in the NGF-stimu-
lated cells (Fig. 1b).
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A specific NGF receptor inhibitor prevents NGF-
induced effects on Lcn2 gene and protein expression
To confirm that the changes in Lcn2 gene and protein
expression were mediated through NGF receptor signaling,
experiments were undertaken in the presence of Ro
08-2750, a non-peptide inhibitor of NGF that selectively
binds to p75NTR at the concentration used in the current
study. Rat AF cells were co-incubated with NGF (100 ng/
mL/day) with and without Ro 08-2750 (10 nM/day) for
5 days and Lcn2 and Mmp9 gene expression was analyzed
by real-time PCR. The NGF-induced upregulation of Lcn2
was significantly inhibited by Ro 08-2750 (Fig. 2a). NGF
alone had no significant effects on Mmp9 gene expression
(Fig. 2b) consistent with results from the microarray ana-
lysis (not shown). Similarly, co-incubation of AF cells with
NGF and Ro 08-2750 did not influence Mmp9 gene
expression.
Effects of Ro 08-2750 on NGF-induced changes in Lcn2
protein expression were studied by western immunoblot-
ting and immunofluorescence. Following NGF stimulation
at a concentration of 100 ng/mL/day for 5 days, Lcn2
protein expression is increased in AF cells but inhibited in
the presence of Ro 08-2750 (Fig. 2c, d). MMP9 protein
expression was increased following treatment of AF cells
with NGF. Similar to the results seen on Lcn2 expression,
no change in levels of MMP9 was observed when cells
were treated with NGF in the presence of Ro 08-2750.
NGF treatment of AF cells enhances 125-kDa
gelatinase activity
Lcn2 has been shown to form a complex with MMP9 to
stabilize and protect MMP9 activity [16] and hence has the
potential to enhance catabolic activity through this
mechanism. To establish whether this was potentially the
case in our model system, we undertook a series of studies
using gelatin zymography (Fig. 3). In basal cultures, gel-
atin zymography showed that culture media from AF cul-
tures were rich in 62-, 72-, 82-, 92-, and 125-kDa MMP
activity. MMP activity at 92- and 82- kDa and 72- and
62-kDa has previously been determined to represent latent
and active forms of MMP9 and MMP2, respectively,
whereas 125-kDa activity has been demonstrated to be due
to an Lcn2-MMP9 complex [16]. When NGF is added to
the cultures, the 125-kDa activity was increased signifi-
cantly and inhibited by addition of the NGF inhibitor Ro
082750 (Fig. 3).
Effects of NGF on GAG release in AF cell cultures
When AF cells are cultured in monolayer, GAG is depos-
ited in the pericellular matrix [17]. To establish whether
NGF had pro-catabolic effects on GAG release, AF cells
were cultured in the presence of NGF and GAG in the
medium assessed. NGF at a concentration of 100 ng/mL
significantly increased the amount of GAG within the
media (Fig. 4) over a 5-day incubation although the effect
is lower than seen with 10 ng/mL IL1b following 24-h
incubation. The pro-catabolic effect of NGF was inhibited
by the presence of the specific NGF inhibitor Ro 08-2750.
Ro 08-2750 had no effect on basal levels of GAG release.
Identification of Lcn2-MMP9 complex and MMP9
activity in culture medium
To confirm that the 125-kDa gelatinase is an Lcn2-MMP9
complex, the collected media were subjected to immuno-
precipitation with an anti-MMP9 antibody. Pull-down
products were then immunoblotted with anti-MMP9 and
A BFig. 1 Effect of NGF on Lcn2
gene and protein expression in
AF cells. a Real-time PCR.
Lcn2 expression is significantly
increased (18.00 ± 1.92-fold)
following NGF stimulation.
b Western immunoblotting
analysis shows a significant
increase in Lcn2 protein
(4.3 ± 1.5-fold) following NGF
stimulation. (n = 5,
***P\ 0.001)
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anti-Lcn2 antibodies, respectively (Fig. 5a). Both MMP9
and Lcn2 release was increased following NGF stimulation
and inhibited in the presence of Ro 08-2750. MMP9
activity in the medium was assayed by FRET functional
analysis which demonstrated significantly increased activ-
ity of MMP9 following NGF stimulation which was
inhibited by the presence of Ro 08-2750 (Fig. 5b).
Discussion
In this study, we have observed that NGF, which is likely
to play a role in nerve ingrowth into the degenerated IVD
[5, 18], may also act as a catabolic factor promoting disc
degeneration [15]. The observation that NGF induced
overexpression of lipocalin 2 to enhance MMP9 activity in
AF cells is previously unreported.
Lcn2 is a multifunctional 25-kDa protein that has roles
in innate immunity and tumourigenesis. Also known as
neutrophil gelatinase-associated lipocalin (NGAL), Lcn2 is
now recognized as an adipokine as it is predominantly
produced by white adipose tissue [19]. Lcn2 has recently
been identified in growth plate chondrocytes [20] where
expression is modulated by IL-1b, leptin, adiponectin,
lipopolysaccharides, and dexamethasone. The function of
Lcn2 in cartilage and IVD tissue is currently unknown.
However, activity in these tissues is most probably related
to one or more of the multifaceted functions of this mol-
ecule identified in other tissues. These include promoting
angiogenesis [21] and enhancing matrix degradation
through interactions with MMP9 [16]. With respect to the
latter activity, dimerization of Lcn2 with proMMP9
appears to enhance activation of the enzyme by plasma
kallikrein and protects the enzyme from degradation [22].
Lcn2 is increased in the synovial fluid of patients with OA
where it also acts to protect MMP9 from degradation and
enhance MMP9-induced cartilage breakdown [16]. This
activity, maintaining MMP9 protein, is likely to explain the
observations in the current study where it shows increased
expression of MMP9 protein but no change in gene
expression in the AF cultures treated with NGF. Similar
activity in vivo, if present, in IVD would be expected to
enhance tissue degeneration and also potentially influence
neoangiogenesis as seen in tumor models [23].
Overexpression of MMPs is clearly associated with both
osteoarthritis and IVD degeneration [12]. In the current
study, our microarray results indicated that NGF increases
bFig. 2 Ro 08-2750 decreases NGF-induced upregulation of Lcn2
expression in AF cells. a Upregulation (16.23 ± 2.62-fold) of Lcn2
expression by 100 ng/mL NGF was significantly decreased in the
presence of 10 nM Ro 08-2750 (5.77 ± 2.53-fold). n = 6.
***P\ 0.001 compared with control, ###P\ 0.001 compared with
NGF. b NGF had no significantly upregulated effect on Mmp9 gene
expression (n = 10, NGF vs control, P = 0.095). c Upregulated Lcn2
by NGF was inhibited by Ro 08-2750 (n = 5, NGF vs control,
**P\ 0.01; NGF vs NGF ? Ro 08-2750, ##P\ 0.01). d Immuno-
fluorescence showed increased expression of Lcn2 and MMP9 protein
following stimulation by NGF only in the absence of Ro 08-2750.
a No stimulation. b Cells incubated with NGF. c Cells incubated with
Ro 08-2750. d Cells incubated with NGF and Ro 08-2750. (n = 3,
original magnification 91000)
Fig. 3 Basal and NGF induction of Lcn2-MMP9 125-kDa gelatinase
activity is inhibited by 10 nM Ro 08-2750. Lcn2-MMP9 complex
activity was upregulated by 100 nM NGF stimulation (NGF vs
control, 2.75 ± 0.67-fold, *P = 0.046) and inhibited by treatment
with Ro 08-2750 (NGF vs NGF ? Ro 08-2750, #P = 0.023). Upper
panel was a representative gel and lower panel was the semiquan-
titative data (n = 3)
Fig. 4 Ro 08-2750 prevents NGF-induced GAG release in AF cell
cultures. GAG release was significantly increased by NGF stimulation
that was inhibited by treatment Ro 08-2750. IL-1b (10 ng/mL for
24 h) served as positive control for GAG release. (n = 6, *P\ 0.05,
***P\ 0.001)
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expression of a number of MMPs such as MMP3 and
MMP13 consistent with previous investigations that have
shown similar activity of NGF in other tissues and cell
systems, including smooth muscle cells and pancreatic
cancer cells [13, 24]. Increased expression of proteinases in
IVD degeneration is presumably predominantly through
the activity of catabolic cytokines such as IL-1b. Indeed,
whilst we were able to demonstrate an effect of NGF on
release of GAGs into the media of AF cells in culture, this
was less than that seen with IL-1b. Although altered levels
of GAG in the media are likely to be due to proteolytic
activity and release from pericellular matrix, we have not
excluded the possibility that increased GAG production
may also contribute to the elevated GAG in the media.
However, our observations suggest a potentially important
role for NGF in the maintenance of Lcn2-MMP9 complex
stability and hence activity in IVD degeneration. Thus, as
NGF may not only regulate neuronal in-growth but also
influence the production of MMPs and neoangiogenesis
[14], it may be a prime target for intervention in the course
of IVD degeneration to help ameliorate pain and rate of
disease progression.
We have obtained initial information on the pathways by
which NGF influences AF gene and protein expression.
NGF binds to both p75NTR and TrkA NGF receptors
(NGFR). p75 is a low affinity NGFR to which all neuro-
trophins bind, whereas TrkA is a member of the neuro-
trophic tyrosine kinase receptor (NTKR) family and binds
NGF with high affinity. In the presence of TrkA NGFR,
p75NTR participates in the formation of high-affinity
binding sites resulting in enhanced NGF responsiveness
[25, 26]. Signaling through TrkA NGFR results in activa-
tion of a signal cascade including the MAPK-Ras-Erk
pathway, phospholipase C and PI3 kinase [27]. The
observation that Ro 08-2750, a non-peptide inhibitor of
NGF that binds the NGF dimer and inhibits binding to both
p75NTR and TrkA increased expression of Lcn2 in the
NGF treated AF cells supports a direct role for NGF-NGFR
interactions in regulating AF cell function which may be
amenable to therapeutic intervention.
A variety of animal models including bovine, canine,
rabbit, rat, and mouse have been used to study IVD
degeneration or regeneration in place of human samples
[28–30]. In vitro studies that identify potential catabolic
mechanisms involved in deserve consideration when for-
mulating a clinical solution to degenerative disc disease. In
the current study, we used cells between 3 and 5 passages.
Optimal in vitro studies would be with cells at passage 1 or
2 to mitigate against dedifferentiation and senescence. As
such these studies will need to be followed up by appro-
priate in vivo studies. Rat-tail IVD would appear to be a
good model system for both in vitro and in vivo studies [31,
32]. We believe that the data in this study support further
investigation of the potential of NGF-targeted therapy in
the management of IVD disease [6, 33].
Conclusions
In summary, we have shown for the first time that NGF
increases expression of Lcn2 in AF cells and formation of
an Lcn2-MMP9 complex promotes a pro-catabolic phe-
notype. Novel treatments targeting NGF/NGF receptors
have the potential to influence a range of adverse biological
responses including neurite and vascular infiltration as well
A
B
Fig. 5 Presence of Lcn2-MMP9 complex and MMP9 activity in
cultured medium. a By immunoprecipitation (IP), Lcn2-MMP9
complex was identified and upregulated by NGF stimulation (NGF
vs control, Lcn2 1.95 ± 0.5-fold; MMP9 2.1 ± 0.6-fold, *P = 0.006
and 0.01, respectively) and inhibited by treatment with Ro 08-2750
(NGF vs NGF ? Ro 08-2750, #P = 0.022 and 0.02, respectively).
Upper panel was a representative gel (IB immunoblotting) and lower
panel was the semiquantitative data (n = 6). b By FRET assay,
MMP9 activity (lM/min/lL) was upregulated by NGF stimulation
(Control, 16.06 ± 4.09; NGF, 19.12 ± 4.0; Ro 08-2750,
13.6 ± 3.35; NGF ? Ro 08-2750, 14.83 ± 3.66; *NGF vs control,
P = 0.039) and inhibited by treatment with Ro 08-2750 (NGF vs
NGF ? Ro 08-2750, #P = 0.012) (n = 6)
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as tissue degeneration which result in the clinical symp-
toms and pathology.
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